{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.50","upperLimit":"38.75","value":"13.02"},{"groupId":"OG001","lowerLimit":"5.00","upperLimit":"43.39","value":"15.65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"The median daily dose of pain medications is provided as morphine equivalents.","dispersionType":"Full Range","groups":[{"description":"Patients will receive six doses of Uproleselan intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.","id":"OG000","title":"Uproleselan + Standard of Care Melphalan"},{"description":"Patients will receive six doses of placebo intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.","id":"OG001","title":"Placebo + Standard of Care Melphalan"}],"paramType":"MEDIAN","populationDescription":"The number of participants analyzed at each time point may differ from the overall number of participants analyzed because the data was not collected. One patient in the placebo + standard of care melphalan arm was not evaluable for the outcome measure.","reportingStatus":"POSTED","timeFrame":"Through date of discharge (up to be 18 days)","title":"Median Daily Dose of Pain Medications","type":"SECONDARY","unitOfMeasure":"mg morphine equivalents"}